Literature DB >> 10362982

Tissue perfusion as a key underlying concept of pressure ulcer development and treatment.

E F Wywialowski1.   

Abstract

The purpose of this article is to refine and advance the theory that tissue perfusion is the key concept in the development and delayed healing of pressure ulcers. The person likely to have (be at risk for) pressure ulcers is at greater risk for inadequate tissue perfusion generally and specifically at pressure points. Accordingly, the tissue perfusion theory of pressure ulcer development states that the factors that contribute to inadequate tissue perfusion should be used to predict (identify risk factors for) pressure ulcer development and delayed healing. Factors influencing a person's adequacy of tissue perfusion need to be assessed to identify risk for pressure ulcers. In addition, adequate tissue perfusion needs to be maintained to provide for healing of such wounds. Current beliefs about the causes and prevention of pressure ulcers are described. Physiologic components of the tissue perfusion theory are discussed: cellular exchange of nutrients and wastes, autoregulation of blood flow at the cellular level, and regulatory mechanisms that affect tissue perfusion when it is significantly compromised. The North American Nursing Diagnosis Association (NANDA) framework is used to classify or group examples of common pathophysiologic, treatment-related, situational, and maturational factors. Implications for research, practice, and education also are discussed.

Entities:  

Mesh:

Year:  1999        PMID: 10362982     DOI: 10.1016/s1062-0303(99)90003-1

Source DB:  PubMed          Journal:  J Vasc Nurs        ISSN: 1062-0303


  2 in total

Review 1.  The biomechanics of sitting-acquired pressure ulcers in patients with spinal cord injury or lesions.

Authors:  Amit Gefen
Journal:  Int Wound J       Date:  2007-09       Impact factor: 3.315

Review 2.  Evaluation of antidecubitus mattresses.

Authors:  A Jonsson; M Lindén; M Lindgren; L-A Malmqvist; Y Bäcklund
Journal:  Med Biol Eng Comput       Date:  2005-09       Impact factor: 3.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.